galapagosgilead

Galapagos retains European commercialization rights. Gilead remains responsible for filgotinib outside Europe, including in Japan where filgotinib is approved ...

2021年2月10日 — Gilead has now said it would give up on a U.S. approval for filgotinib in rheumatoid arthritis, pay Galapagos €160 million to take over most ...

2019年8月23日 — As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outstanding share ...

2021年2月10日 — Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are ...

2015年12月17日 — Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases.

2020年12月15日 — Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease (IBD).

2019年7月14日 — Gilead will have access to Galapagos' established research base, which includes more than 500 scientists, and to Galapagos' unique platform, ...

Galapagos lists on the NASDAQ (ticker symbol: GLPG). 2019. Gilead headquarter buildings with a sign featuring Gilead's logo. Galapagos enters into a ...

2019年7月14日 — Gilead will maintain option rights to Galapagos' programs through the 10-year term of the collaboration and for up to an additional three years ...

Under the terms of the agreement, Gilead made a one-time payment of $15 million to Galapagos. From 1 April 2022, Galapagos is solely responsible for all ...